Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 17

1.

Multi-Drug/Gene NASH Therapy Delivery and Selective Hyperspectral NIR Imaging Using Chirality-Sorted Single-Walled Carbon Nanotubes.

Hasan MT, Campbell E, Sizova O, Lyle V, Akkaraju G, Kirkpatrick DL, Naumov AV.

Cancers (Basel). 2019 Aug 14;11(8). pii: E1175. doi: 10.3390/cancers11081175.

2.

In vitro and in vivo assessment of the abuse potential of PF614, a novel BIO-MD™ prodrug of oxycodone.

Kirkpatrick DL, Schmidt WK, Morales R, Cremin J, Seroogy J, Husfeld C, Jenkins T.

J Opioid Manag. 2017 Jan/Feb;13(1):39-49. doi: 10.5055/jom.2017.0366.

PMID:
28345745
3.

Clinically Evaluated Cancer Drugs Inhibiting Redox Signaling.

Kirkpatrick DL, Powis G.

Antioxid Redox Signal. 2017 Feb 20;26(6):262-273. doi: 10.1089/ars.2016.6633. Epub 2016 Apr 22. Review.

4.

Carbon Nanotubes: Solution for the Therapeutic Delivery of siRNA?

Kirkpatrick DL, Weiss M, Naumov A, Bartholomeusz G, Weisman RB, Gliko O.

Materials (Basel). 2012 Feb 13;5(2):278-301. doi: 10.3390/ma5020278.

5.

Molecular pharmacology and antitumor activity of PHT-427, a novel Akt/phosphatidylinositide-dependent protein kinase 1 pleckstrin homology domain inhibitor.

Meuillet EJ, Zuohe S, Lemos R, Ihle N, Kingston J, Watkins R, Moses SA, Zhang S, Du-Cuny L, Herbst R, Jacoby JJ, Zhou LL, Ahad AM, Mash EA, Kirkpatrick DL, Powis G.

Mol Cancer Ther. 2010 Mar;9(3):706-17. doi: 10.1158/1535-7163.MCT-09-0985. Epub 2010 Mar 2.

6.

Cellular and in vivo activity of a novel PI3K inhibitor, PX-866, against human glioblastoma.

Koul D, Shen R, Kim YW, Kondo Y, Lu Y, Bankson J, Ronen SM, Kirkpatrick DL, Powis G, Yung WK.

Neuro Oncol. 2010 Jun;12(6):559-69. doi: 10.1093/neuonc/nop058. Epub 2010 Feb 15.

7.

Mutations in the phosphatidylinositol-3-kinase pathway predict for antitumor activity of the inhibitor PX-866 whereas oncogenic Ras is a dominant predictor for resistance.

Ihle NT, Lemos R Jr, Wipf P, Yacoub A, Mitchell C, Siwak D, Mills GB, Dent P, Kirkpatrick DL, Powis G.

Cancer Res. 2009 Jan 1;69(1):143-50. doi: 10.1158/0008-5472.CAN-07-6656.

8.

Molecular mechanisms for the activity of PX-478, an antitumor inhibitor of the hypoxia-inducible factor-1alpha.

Koh MY, Spivak-Kroizman T, Venturini S, Welsh S, Williams RR, Kirkpatrick DL, Powis G.

Mol Cancer Ther. 2008 Jan;7(1):90-100. doi: 10.1158/1535-7163.MCT-07-0463.

9.

Thioredoxin signaling as a target for cancer therapy.

Powis G, Kirkpatrick DL.

Curr Opin Pharmacol. 2007 Aug;7(4):392-7. Epub 2007 Jul 3. Review.

PMID:
17611157
10.

A Phase I pharmacokinetic and pharmacodynamic study of PX-12, a novel inhibitor of thioredoxin-1, in patients with advanced solid tumors.

Ramanathan RK, Kirkpatrick DL, Belani CP, Friedland D, Green SB, Chow HH, Cordova CA, Stratton SP, Sharlow ER, Baker A, Dragovich T.

Clin Cancer Res. 2007 Apr 1;13(7):2109-14.

11.

Practicalities of drugging the phosphatidylinositol-3-kinase/Akt cell survival signaling pathway.

Powis G, Ihle N, Kirkpatrick DL.

Clin Cancer Res. 2006 May 15;12(10):2964-6. No abstract available.

12.

Molecular pharmacology and antitumor activity of palmarumycin-based inhibitors of thioredoxin reductase.

Powis G, Wipf P, Lynch SM, Birmingham A, Kirkpatrick DL.

Mol Cancer Ther. 2006 Mar;5(3):630-6.

13.

The antitumor thioredoxin-1 inhibitor PX-12 (1-methylpropyl 2-imidazolyl disulfide) decreases thioredoxin-1 and VEGF levels in cancer patient plasma.

Baker AF, Dragovich T, Tate WR, Ramanathan RK, Roe D, Hsu CH, Kirkpatrick DL, Powis G.

J Lab Clin Med. 2006 Feb;147(2):83-90.

14.

The phosphatidylinositol-3-kinase inhibitor PX-866 overcomes resistance to the epidermal growth factor receptor inhibitor gefitinib in A-549 human non-small cell lung cancer xenografts.

Ihle NT, Paine-Murrieta G, Berggren MI, Baker A, Tate WR, Wipf P, Abraham RT, Kirkpatrick DL, Powis G.

Mol Cancer Ther. 2005 Sep;4(9):1349-57.

15.
16.

Solubility, ionization, and partitioning behavior of unsymmetrical disulfide compounds: alkyl 2-imidazolyl disulfides.

Hashash A, Kirkpatrick DL, Lazo JS, Block LH.

J Pharm Sci. 2002 Jul;91(7):1686-92.

PMID:
12115830
17.

Normal-phase and stability-indicating reversed-phase high-performance liquid chromatographic methods for the determination of the novel antitumor agent: 1-methylpropyl-2-imidazolyldisulfide.

Hashash A, Kirkpatrick DL, Egorin MJ, Block LH, Lazo JS.

J Chromatogr B Analyt Technol Biomed Life Sci. 2002 Mar 5;768(2):239-46.

PMID:
11888051

Supplemental Content

Loading ...
Support Center